[Chemotherapeutic effectiveness of gentamycin, tobramycin and sisomycin in Pseudomonas aeruginosa pyelonephritis in rats compared with dioxidine]. 1984

T A Zinchenko, and E A Rudzit, and I B Zukakova, and L I Lisitsa

The chemotherapeutic efficacy of gentamicin, tobramycin, sisomicin and dioxydin was studied and compared in rats with hematogenic obturation P. aeruginosa pyelonephritis. The drugs were injected intramuscularly in doses of 5, 8, 8 and 50 mg/kg, respectively for 7 days a day after infection. It was shown that on prolongation of the period of the treatment estimation from 24 hours to 7 days after discontinuation of the drug use a significant decrease was observed in the therapeutic efficacy of dioxydin, gentamicin and especially tobramycin. As for sisomicin, the decrease was insignificant. Dioxydin and gentamicin had a similar therapeutic effect at the early and late periods of their estimation after discontinuation of the treatment. They were inferior to tobramycin with respect to the early results and superior to it with respect to the late results. The chemotherapeutic efficacy of sisomycin in both the cases was higher than that of tobramycin, gentamicin and dioxydin.

UI MeSH Term Description Entries
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D011704 Pyelonephritis Inflammation of the KIDNEY involving the renal parenchyma (the NEPHRONS); KIDNEY PELVIS; and KIDNEY CALICES. It is characterized by ABDOMINAL PAIN; FEVER; NAUSEA; VOMITING; and occasionally DIARRHEA. Necrotizing Pyelonephritis,Pyelonephritis, Acute Necrotizing,Pyelonephritides
D011810 Quinoxalines Quinoxaline
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D005260 Female Females
D005839 Gentamicins A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS. Gentamicin Sulfate (USP),Gentamycin,G-Myticin,Garamycin,Gentacycol,Gentamicin,Gentamicin Sulfate,Gentamycins,Gentavet,Genticin,G Myticin,GMyticin,Sulfate, Gentamicin
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D012853 Sisomicin Antibiotic produced by Micromonospora inyoensis. It is closely related to gentamicin C1A, one of the components of the gentamicin complex (GENTAMICINS). Sisomycin,Sissomicin,4,5-Dehydrogentamicin,Antibiotic 6640,Extramycin,Pathomycin,Rickamicin,Sch-13475,Siseptin,Sisomicin Sulfate,Sisomicin Sulfate (2:5) Salt,Sizomycin,4,5 Dehydrogentamicin,Sch 13475,Sch13475
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

T A Zinchenko, and E A Rudzit, and I B Zukakova, and L I Lisitsa
January 1982, Farmakologiia i toksikologiia,
T A Zinchenko, and E A Rudzit, and I B Zukakova, and L I Lisitsa
April 1978, Antibiotiki,
T A Zinchenko, and E A Rudzit, and I B Zukakova, and L I Lisitsa
August 1970, Orvosi hetilap,
T A Zinchenko, and E A Rudzit, and I B Zukakova, and L I Lisitsa
January 1982, Archivio per le scienze mediche,
T A Zinchenko, and E A Rudzit, and I B Zukakova, and L I Lisitsa
March 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society,
T A Zinchenko, and E A Rudzit, and I B Zukakova, and L I Lisitsa
May 2015, Molecular pharmaceutics,
T A Zinchenko, and E A Rudzit, and I B Zukakova, and L I Lisitsa
July 1975, Antimicrobial agents and chemotherapy,
T A Zinchenko, and E A Rudzit, and I B Zukakova, and L I Lisitsa
September 1977, Antimicrobial agents and chemotherapy,
T A Zinchenko, and E A Rudzit, and I B Zukakova, and L I Lisitsa
January 1978, Infection,
T A Zinchenko, and E A Rudzit, and I B Zukakova, and L I Lisitsa
September 1979, The Medical journal of Australia,
Copied contents to your clipboard!